Journal ArticleDOI
The safety profile of infliximab in patients with Crohn's disease: The Mayo Clinic experience in 500 patients
Jean-Frederic Colombel,Edward V. Loftus,William J. Tremaine,Laurence J. Egan,W. Scott Harmsen,Cathy D. Schleck,Alan R. Zinsmeister,William J. Sandborn +7 more
Reads0
Chats0
TLDR
Short- and long-term infliximab therapy is generally well tolerated, however, clinicians must be vigilant for the occurrence of infrequent but serious events, including serum sickness-like reaction, opportunistic infection and sepsis, and autoimmune disorders.About:
This article is published in Gastroenterology.The article was published on 2004-01-01. It has received 883 citations till now. The article focuses on the topics: Infliximab & Adverse effect.read more
Citations
More filters
Journal ArticleDOI
Infliximab for induction and maintenance therapy for ulcerative colitis.
Paul Rutgeerts,William J. Sandborn,Brian G. Feagan,Walter Reinisch,Allan Olson,Jewel Johanns,Suzanne Travers,Daniel Rachmilewitz,Stephen B. Hanauer,Gary R. Lichtenstein,Willem J.S. de Villiers,Daniel H. Present,Bruce E. Sands,Jean-Frederic Colombel +13 more
TL;DR: Patients with moderate-to-severe active ulcerative colitis treated with infliximab at weeks 0, 2, and 6 and every eight weeks thereafter were more likely to have a clinical response at weeks 8, 30, and 54 than were those receiving placebo.
Journal ArticleDOI
Microbial Influences in Inflammatory Bowel Diseases
TL;DR: Altered microbial composition and function in inflammatory bowel diseases result in increased immune stimulation, epithelial dysfunction, or enhanced mucosal permeability, which should lead to selective targeted interventions that correct underlying abnormalities and induce sustained and predictable therapeutic responses.
Journal ArticleDOI
Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee.
Asher Kornbluth,David B. Sachar +1 more
TL;DR: Guidelines for clinical practice are aimed to indicate preferred approaches to medical problems as established by scientifically valid research, and are applicable to all physicians who address the subject regardless of specialty training or interests.
Journal ArticleDOI
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management
Axel Dignass,G. Van Assche,James O. Lindsay,Marc Lémann,Johan D. Söderholm,Jean-Frederic Colombel,Silvio Danese,André D'Hoore,Miquel A. Gassull,Fernando Gomollón,Daan W. Hommes,Pierre Michetti,Colm O'Morain,Tom Øresland,Alastair Windsor,Eduard F. Stange,Simon Travis +16 more
TL;DR: This paper is the second in a series of three publications relating to the European evidence-based consensus on the diagnosis and management of Crohn's disease and concerns the management of active disease, maintenance of medically induced remission and surgery.
Journal ArticleDOI
Guidelines for the management of inflammatory bowel disease in adults
TL;DR: These guidelines, commissioned by the Clinical Services’ Committee of the British Society of Gastroenterology, provide an evidence based document describing good clinical practice for investigation and treatment of patients with IBD in the United Kingdom.
References
More filters
Journal ArticleDOI
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Stephen B. Hanauer,Brian G. Feagan,Gary R. Lichtenstein,Lloyd Mayer,Stefan Schreiber,Jean-Frederic Colombel,Daniel Rachmilewitz,Douglas C. Wolf,Allan Olson,Weihang Bao,Paul Rutgeerts +10 more
TL;DR: Patients with Crohn's disease who respond to an initial dose of infliximab are more likely to be in remission at weeks 30 and 54, to discontinue corticosteroids, and to maintain their response for a longer period of time, if inflIXimab treatment is maintained every 8 weeks.
Journal ArticleDOI
Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent
Joseph Keane,Sharon K. Gershon,Robert P. Wise,Elizabeth Mirabile-Levens,John Kasznica,William D. Schwieterman,Jeffrey Siegel,M. Miles Braun +7 more
TL;DR: Infliximab is a humanized antibody against tumor necrosis factor α (TNF-α) that is used in the treatment of Crohn's disease and rheumatoid arthritis but there is no direct evidence of a protective role of TNF- α in patients with tuberculosis.
Journal ArticleDOI
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.
Stephan R. Targan,Stephen B. Hanauer,S. J. H. Van Deventer,Lloyd Mayer,Daniel H. Present,T. Braakman,K. L. Dewoody,T. F. Schaible,Paul Rutgeerts +8 more
TL;DR: A 12-week multicenter, double-blind, placebo-controlled trial of cA2 in 108 patients with moderate-to-severe Crohn's disease that was resistant to treatment, finding clinical response, the primary end point, was a reduction of 70 or more points in the score on theCrohn's Disease Activity Index at four weeks.
Journal ArticleDOI
Infliximab for the treatment of fistulas in patients with Crohn's disease.
Daniel H. Present,Paul Rutgeerts,Stephan R. Targan,Stephen B. Hanauer,Lloyd Mayer,R. A. van Hogezand,Daniel K. Podolsky,Bruce E. Sands,T. Braakman,K. L. Dewoody,Th.F. Schaible,S. J. H. Van Deventer +11 more
TL;DR: Infliximab is an efficacious treatment for fistulas in patients with Crohn's disease and the most common adverse events for patients treated with infliximab were headache, abscess, upper respiratory tract infection, and fatigue.
Journal ArticleDOI
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
Filip Baert,Maja Noman,Severine Vermeire,Gert Van Assche,Geert D' Haens,An Carbonez,Paul Rutgeerts +6 more
TL;DR: The development of antibodies against infliximab is associated with an increased risk of infusion reactions and a reduced duration of response to treatment, and concomitant immunosuppressive therapy reduces the magnitude of the immunogenic response.
Related Papers (5)
Infliximab Maintenance Therapy for Fistulizing Crohn's Disease
Bruce E. Sands,Frank H. Anderson,Charles N. Bernstein,William Y. Chey,Brian G. Feagan,Richard N. Fedorak,Michael A. Kamm,Joshua R. Korzenik,Bret A. Lashner,Jane E. Onken,Daniel Rachmilewitz,Paul Rutgeerts,Gary Wild,Douglas C. Wolf,Paul Marsters,Suzanne Travers,Marion Blank,Sander J. H. van Deventer +17 more